Zhican Qu
Chief Executive Officer & Founder Nanolattix
Seminars
Wednesday 5th November 2025
ADC & RDC Theranostic Precision Oncology: Synergistic Therapeutics From Diagnosis to Treatment
2:00 pm
- Integrating ADC and RDC theranostic modalities to form a powerful next-generation therapeutic strategy
- Overcoming drug resistance and tumor heterogeneity for more effective cancer eradication and significantly improve oncology SoC
- Data highlights from clinical-stage T320 (ADC) and preclinical molecules RT01 (RDC), B836 (Bispecific ADC), and RB02 (Bispecific RDC)
